Lexaria Bioscience Corp. LXRP Archives - Page 7 of 27

TuesdayAug 13, 2019 9:49 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) Subsidiary Receives Health Canada Cannabis R&D License

Biotechnology company and drug delivery platform innovator Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) today announced that Health Canada has issued cannabis Research and Development (“R&D”) license LIC-7NONT76UNW-2019 to its subsidiary, Lexaria CanPharm ULC. According to the update, the license, which carries a four-year term unless renewed, is effective immediately and will allow one of the country’s newest and most advanced formulation laboratories to conduct extensive investigatory work in THC and CBD delivery using optimized, proprietary formulations and techniques. The purpose-built laboratory is permitted at local and federal levels and fully outfitted to produce DehydraTECH(TM) infusions and includes two different…

ThursdayAug 08, 2019 10:07 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Completes Initial R&D Program with the National Research Council of Canada

Biotechnology company and drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) today announced successful completion of its Master Collaborative Research Agreement (“the R&D Program”) with the National Research Council of Canada (“NRC”). The R&D program sought to investigate technical aspects and new opportunities associated with bioavailability enhancement of lipophilic active ingredient compositions using Lexaria’s patented DehydraTECH(TM) technology with a primary goal to determine whether, through its processing, DehydraTECH causes the formation of a new molecular entity (“NME”). According to the update, all evidence aligns to confirm that no covalent-bonded NME is created with Lexaria’s technology. Processes or technologies…

TuesdayAug 06, 2019 11:18 am

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Reviews Expansion of Client Base, Noting Unprecedented Number of License Agreements

Lexaria’s patented DehydraTECH technology improves taste, achieves higher absorption rates and promotes fast onset of bioactive compounds, including nicotine and cannabinoids Nine corporate licensees have signed a total of 11 definitive contracts to use DehydraTECH technology in innovative beverages, edibles and oral products Lexaria expects to experience unprecedented revenue growth as many of its clients plan aggressive rollouts and growth for their product lines Biotechnology company and drug delivery platform innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is expanding its family of existing licensees and partners with an impressive lineup of new corporate licensees for use of Lexaria’s patented DehydraTECH…

MondayAug 05, 2019 12:02 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Paves Way for New Cannabis Brand, B2B Sales through Partnership with Alcohol-Free Beverage Maker

Lexaria Bioscience’s revolutionary DehydraTECH technology enables cannabis consumers to experience rapid-on, rapid-off effects in non-smoked formulations A just-announced joint manufacturing partnership between Lexaria and alcohol-free beverage maker Hill Street Beverage Company is paving the way for wider distribution of Lexaria’s platform Hill Street is the only company to have gained licenses to use DehydraTECH on a global basis, taking advantage of Lexaria’s multiple international granted and pending patents By 2024, cannabis-infused beverage sales are expected to rise by nearly 15 times from last year’s revenues of $89 million The exploding interest in cannabis products and in new ways of enjoying…

FridayAug 02, 2019 9:50 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) Retains Integra Consulting Group LLC to Provide Investor Relations Services

Biotechnology company and drug delivery platform innovator Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) today announced that it has engaged Integra Consulting Group LLC to provide investor relations services to the company in compliance with regulatory guidelines. According to the update, Integra leverages decades of market experience with a robust proprietary database and partners with select underexposed and undervalued emerging growth companies to continuously maximize market visibility throughout their clients’ different development cycles. Integra will work with Lexaria to provide outreach to communicate its message to maximize corporate visibility, seek out opportunities to deliver audience-targeted presentations and utilize web-casting capabilities…

TuesdayJul 30, 2019 10:12 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Summarizes DehydraTECH(TM) Technology Licensees

Biotechnology company and drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) today reported on its existing technology licensees that have entered definitive contracts to use its revolutionary DehydraTECH(TM) absorption technology within their existing and emerging brands. “The first half of 2019 delivered a period of unprecedented achievements for Lexaria. We signed more license agreements than ever before in our Company’s history, many of which were larger in scope than anything previous,” Lexaria Chief Executive Officer Chris Bunka said in the news release. “We also launched our brand-new business division Lexaria Nicotine which is disrupting nicotine delivery methods that…

ThursdayJul 25, 2019 10:00 am

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Agreement Increases Reach of Ingested Cannabis Absorption Technology

Cannabis users have historically preferred to inhale smoke from the burned plant in order to achieve rapid-onset absorption of its properties, but Lexaria Bioscience is making it possible to achieve similar results through oral ingestion Lexaria’s revolutionary DehydraTECH technology allows cannabis users to eliminate the unhealthy effects of smoking from their routines, and the product is being tested with nicotine as well Cannabis-infused edibles sales are expected to climb from about $1 billion currently to about $4.1 billion by 2022 Consumable bioactive product innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) will expand the reach of its revolutionary DehydraTECH technology…

WednesdayJul 24, 2019 10:04 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Enters Global Manufacturing & Licensing Partnership with Hill Street Beverage Co. (TSX.V: BEER)

Biotechnology company and drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) today announced a multi-faceted expansion of its relationship with Hill Street Beverage Company Inc. (TSX.V: BEER). According to the update, the companies have entered into a 10-year Joint Manufacturing Partnership (“JMP”) to produce DehydraTECH(TM) commercial products under a new brand, which will be announced. The JMP will produce processed THC cannabis and/or CBD hemp powder for new consumer products under categories including, among others, tablets, capsules, or packets for sale in Canada and for export where permitted. Similar powders as a bulk ingredient for manufacturing processes will…

TuesdayJul 23, 2019 2:51 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Remains Ahead of the Pack with Innovative Delivery Technology

Biotechnology company Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) is the developer of the drug-delivery platform DehydraTECH(TM). The company’s innovative technology promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. An article discussing the company reads, “One of the delivery challenges is the amount of CBD waste created, because the human body can only absorb a small amount of the molecules. DehydraTECH is disrupting this cycle by protecting the product during stomach transit, amplifying intestinal absorption by five to ten times over traditional methods and enabling the drug to bypass first-pass liver metabolism. Third-party lab studies…

TuesdayJul 23, 2019 12:17 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Stands for Responsible Cannabis Use; Is the Industry Taking Adoption Too Far?

As the legal marijuana industry continues to rapidly expand, regulatory bodies in the U.S. and other parts of the world are facing lobby pressure to ensure widespread adoption Companies like Lexaria Bioscience have opposed such developments to ensure responsible and safe introduction of legal cannabis products for medicinal and recreational use Current Lexaria corporate policies go beyond the legislative framework to deliver sensitive products to people in need while also protecting vulnerable community members The multi-million-dollar cannabis industry is growing rapidly. In the U.S. and other parts of the world, there has been a push for legislative changes and the…

Site Search

Company Search

Tag: Lexaria Bioscience Corp. LXRP